Data as of 3:59pm ET
| +0.12 / +2.11%|
The 4 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 8.50, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a +46.55% increase from the last price of 5.80.
The current consensus among 4 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.